Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study

Hepatology

Volumn 51, Issue 6, 2010, Pages 2069-2076

  Bruno, Savino ^a   Crosignani, Andrea ^a   Facciotto, Corinna ^a   Rossi, Sonia ^a   Roffi, Luigi ^a   Redaelli, Alessandro ^b   De Franchis, Roberto ^b,c   Almasio, Piero Luigi ^d   Maisonneuve, Patrick ^e  

^a AO Fatebenefratelli e Oftalmico ^*  (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e PARKINSON INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; ENDOSCOPY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; GENOTYPE; HAZARD RATIO; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77952704228     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23528     Document Type: Article

References (28)

1. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472. (Pubitemid 27078833)
2. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-136. (Pubitemid 30430422)
3. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-749. (Pubitemid 38561455)
4. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. HEPATOLOGY 2006;43:1303-1310. (Pubitemid 43980109)
5. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009;104:1147-1158.
6. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231. (Pubitemid 41772537)
7. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-2261. (Pubitemid 41697288)
8. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
9. Marmo R, Romano M, De Sio I, Peduto A, Caporaso N, Persico M, et al. Decision-making model for a non-invasive diagnosis of compensated liver cirrhosis. Ital J Gastroenterol 1983;25:1-8.
10. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. HEPATOLOGY 1995;21:285-290.
11. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-989.
12. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia: Saunders; 1964:50-64.
13. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with endstage liver disease. HEPATOLOGY 2001;33:464-470. (Pubitemid 32119037)
14. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176.
15. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. HEPATOLOGY 2004;39:280-282. (Pubitemid 38222164)
16. Kondo F, Wada K, Nagato Y, Nakajima T, Kondo Y, Hirooka N, et al. Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. HEPATOLOGY 1989;9:751-755. (Pubitemid 19123525)
17. Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994;20:117-121. (Pubitemid 24043096)
18. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
19. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699. (Pubitemid 26079803)
20. Sorensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. HEPATOLOGY 2006;44:1075-1082. (Pubitemid 44748358)
21. Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006;101:2269-2274. (Pubitemid 44477554)
22. Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007;5:932-937.
23. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-829.
24. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403 [Erratum in: Ann Intern Med 2008;149:844].
25. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007;45:579-587.
26. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684.
27. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009;50:1142-1154.
28. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838 [Erratum in: N Engl J Med 2009;361:1516].